Effects of Argatroban Therapy, Demographic Variables, and Platelet Count on Thrombotic Risks in Heparin-Induced Thrombocytopenia
Authors:
- Bruce E. LewisBLBruce E. Lewis
- Diane E. WallisDWDiane E. Wallis
- Marcie J. HurstingMHMarcie J. Hursting
- Robert L. LevineRLRobert L. Levine
- Fred LeyaFLFred Leya
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosisThrombosis and Haemostasis, 2005
- Heparin-induced thrombocytopenia in the emergency departmentAnnals of Emergency Medicine, 2004
- Risk of thrombosis in patients with malignancy and heparin‐induced thrombocytopeniaAmerican Journal of Hematology, 2004
- Treatment of Heparin-Induced ThrombocytopeniaArchives of internal medicine (1960), 2004
- Heparin-induced thrombocytopenia: twenty-nine years laterJournal of Vascular Surgery, 2003
- Argatroban Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaArchives of internal medicine (1960), 2003
- Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopeniaCatheterization and Cardiovascular Interventions, 2002
- Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958